Results 11 to 20 of about 2,175,372 (155)

Oligomeric Proanthocyanidins Reverse Lenvatinib Resistance in Hepatocellular Carcinoma Through ITGA3-Mediated Pathway [PDF]

Pharmaceuticals
Background: Oligomeric proanthocyanidins (OPCs) are natural polyphenolic compounds with strong antitumor properties and have gained attention as potential agents to overcome drug resistance.
Takayuki Noma, Yuan Li, Yuma Wada, Yuji Morine, Tetsuya Ikemoto, Yu Saito, Shinichiro Yamada, Hiroki Teraoku, Mitsuo Shimada, Ajay Goel   +9 more
doaj   +3 more sources

Tumor peripheral stiffness modulates lenvatinib resistance in HCC preclinical models by regulating FIS1-dependent mitophagy [PDF]

JHEP Reports
Background & Aims: Hepatocellular carcinoma (HCC) displays heterogeneous responses to lenvatinib, with tumor microenvironment (TME) stiffness emerging as a key resistance modulator.
Kunjin Wu, Jing Li, Yunong Fu, Kaibo Yang, Ting Lin, Yaohui Wang, Ming Wang, Yunxiang Long, Fengping Zhang, Bo Cheng, Yuan Li, Cong Wang, Feng Xu, Chang Liu, Kai Qu   +14 more
doaj   +3 more sources

Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma [PDF]

Genes and Diseases
Lenvatinib is widely used as a first-line chemotherapy for advanced hepatocellular carcinoma (HCC), a highly metastatic and recurrent cancer. However, HCC cells often develop resistance to lenvatinib, thus reducing its efficacy.
Mengting Liu, Yixin Liu, Jiahui Zheng, Xiangping An, Jiayong Wen, Fengchi Zhu, Jin Jia, Dan Guo, Nana Chen   +8 more
doaj   +3 more sources

EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis [PDF]

BMC Cancer
Background Lenvatinib resistance significantly limits treatment efficacy in hepatocellular carcinoma (HCC), yet the underlying mechanisms remain poorly understood.
Yibin Zhang, Yucong Lin, Huitang Cai, Tongchong Zhou   +3 more
doaj   +3 more sources

Long non-coding RNA LINC01532 sustains redox homeostasis and accelerates lenvatinib resistance in hepatocellular carcinoma [PDF]

Journal of Advanced Research
Introduction: Lenvatinib is the first-line therapy of hepatocellular carcinoma (HCC) and the high frequency of lenvatinib resistance hinders the improvement of HCC treatment. Since NADPH plays vital roles in antioxidant defense and reductive biosynthesis,
Yang Hu, Muhua Chen, Shiqi Sun, Chunfeng Zhang, Zechang Xin, Xiaoyan Sun, Kun Wang, Kemin Jin, Xiaojuan Du, Baocai Xing, Xiaofeng Liu   +10 more
doaj   +3 more sources

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma, 2023
Meng Tao,1,2 Jing Han,3 Juanyi Shi,1,2 Hao Liao,1,2 Kai Wen,1,2 Weidong Wang,1,2 Sintim Mui,1,2 Huoming Li,1,2 Yongcong Yan,1,2 Zhiyu Xiao1,2 1Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120 ...
Tao M, Han J, Shi J, Liao H, Wen K, Wang W, Mui S, Li H, Yan Y, Xiao Z   +9 more
doaj   +1 more source

Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma

Nature Communications, 2023
Increasing evidence has demonstrated that drug resistance can be acquired in cancer cells by kinase rewiring, which is an obstacle for efficient cancer therapy.
Carmen Oi Ning Leung, Yang Yang, Rainbow Wing Hei Leung, Karl Kam Hei So, Hai Jun Guo, Martina Mang Leng Lei, Gregory Kenneth Muliawan, Yuan Gao, Qian Qian Yu, Jing Ping Yun, Stephanie Ma, Qian Zhao, Terence Kin Wah Lee   +12 more
doaj   +2 more sources

USP1 driven mitotic dysregulation and PLK1 stabilization confer Lenvatinib resistance in hepatocellular carcinoma [PDF]

Journal of Experimental & Clinical Cancer Research
Background Lenvatinib is a first-line therapeutic option for advanced hepatocellular carcinoma (HCC), while acquired resistance severely limits its clinical efficacy.
Yuwei Qiang, Saiyan Bian, Yun Tong, Weiting Chen, Zhangzhi Tang, Chengchen Dai, Mingyu Liu, Banglong Xu, Lihan Jiang, Kexin Ma, Xuyang He, Jinlong Li, Mingbing Xiao, Wenjie Zheng   +13 more
doaj   +2 more sources

Identification of a Prognostic Gene Signature Based on Lenvatinib Resistance in Hepatocellular Carcinoma with Functional Validation of the Key Gene CPB2 [PDF]

Journal of Hepatocellular Carcinoma
Kan Liu,1,* Fei Cheng,2,* Chao Li,3,* Simiao Cheng,4 Junyan Wei,4 Jianbing Wu,1 Shenglan Huang1 1Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s ...
Liu K, Cheng F, Li C, Cheng S, Wei J, Wu J, Huang S   +6 more
doaj   +2 more sources

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Journal of Experimental & Clinical Cancer Research
Background Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with lenvatinib and the rapid emergence
Bixing Zhao, Yang Zhou, Niangmei Cheng, Xiaoyuan Zheng, Geng Chen, Xin Qi, Xiangzhi Zhang, Fei Wang, Qiuyu Zhuang, Yehuda G. Assaraf, Xiaolong Liu, Yingchao Wang, Yongyi Zeng   +12 more
doaj   +2 more sources